BPC July 28 update

Pfizer PFE shares rise on earnings +4%; Offerings for ARCT EPIX SNSS

Price and Volume Movers

Pfizer Inc. (NYSE: PFE) shares closed up 4% to $39.02. The company reported second quarter earnings with revenues of $11.8b, down 11% from the same quarter last year but ahead of analyst estimates. It also slightly raised its 2020 guidance range to $48.6 to $50.6b, up $0.1b from previous guidance.

Soligenix, Inc. (NASDAQ:SNGX) shares closed up 23% to $2.61 following the publication of preclinical (non-human) immunogenicity trials for its CiVax program (COVID-19 vaccine).

ESSA Pharma Inc. (NASDAQ:EPIX) announced after hours that it has commenced an underwritten public offering of its common shares.

Arcturus Therapeutics Holdings Inc. NASDAQ:ARCT) announced that it intends to sell shares of its common stock in an underwritten public offering. After closing down 12% during normal trading hours, shares have fallen a further 5% to $52.86 after hours.

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) also announced that it intends to sell shares of its common stock in an underwritten public offering. Shares are trading down 14% to $0.34 after hours.

-

Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume:

ADVANCERS:

Spring Bank Pharmaceuticals, Inc. (SBPH): $2.57; +42%.

OncoSec Medical Incorporated (ONCS): $3.83; +16%.

XTL Biopharmaceuticals Ltd. (XTLB): $1.81; +16%.

Avidity Biosciences, Inc. (RNA): $28.55; +14%.

TFF Pharmaceuticals, Inc. (TFFP): $7.61; +13%.

DECLINERS:

MediciNova, Inc. (MNOV): $7.40; -33%.

CorMedix Inc. (CRMD): $4.73; -21%.

BiondVax Pharmaceuticals Ltd. (BVXV): $31.41; -17%.

Allena Pharmaceuticals, Inc. (ALNA): $1.30; -16%.

VBI Vaccines Inc. (VBIV): $4.10; -15%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

AMGN – Amgen Inc.
AMG 510
Non-small cell lung cancer (NSCLC)

Phase 2 Phase 2 monotherapy data due 2H 2020.
$142.3 billion

BBIO – BridgeBio Pharma Inc.
Infigratinib
Recurrent Glioblastoma

Phase 2 Phase 0/2 trial initiation announced July 28, 2020.
$3.6 billion

CORT – Corcept Therapeutics Incorporated
Relacorilant (GRADIENT)
Cushing’s syndrome

Phase 3 Phase 3 initiation announced July 28, 2020.
$1.5 billion

CUE – Cue Biopharma Inc.
CUE-101
HPV+ head and neck squamous cell carcinoma (HNSCC)

Phase 1 Phase 1 trial cohort 5 initiation of dosing announced July 28, 2020.
$623.3 million

CYTK – Cytokinetics Incorporated
Omecamtiv mecarbil GALACTIC-HF
Acute heart failure

Phase 3 Phase 3 top-line data due 4Q 2020.
$1.5 billion

KRYS – Krystal Biotech Inc.
B-VEC (Beremagene Geperpavec)
Epidermolysis Bullosa

Phase 3 Phase 3 trial initiation announced July 28, 2020. Top-line data due in 2021.
$809.8 million

LRMR – Larimar Therapeutics Inc.
CTI-1601
Friedreich’s ataxia (FA)

Phase 1 Phase 1 top-line data due 1H 2021.
$163.2 million

MCRB – Seres Therapeutics Inc.
SER-109 - ECOSPOR III
Recurrent C. Difficile infection

Phase 3 Phase 3 data met primary endpoint - August 10, 2020.
$1.7 billion

MCRB – Seres Therapeutics Inc.
SER-155
Gastrointestinal infections, bacteremia and graft versus host disease (GvHD)

Phase 1b Phase 1b trial to be initiated later in 2020.
$1.7 billion

PFE – Pfizer Inc.
PF-06939926
Duchenne muscular dystrophy (DMD)

Phase 3 Phase 3 trial to be initiated 2H 2020.
$214.1 billion

PFE – Pfizer Inc.
IBRANCE (palbociclib) - PENELOPE-B
Early stage breast cancer

Phase 3 Phase 3 data due 2H 2020.
$214.1 billion

PSTV – PLUS THERAPEUTICS Inc.
Rhenium NanoLiposomes (ReSPECT)
Glioma

Phase 1/2 Phase 1 initial data due 2H 2020.
$10.6 million

RETA – Reata Pharmaceuticals Inc.
Bardoxolone (BARCONA)
COVID-19

Phase 2 Phase 2 initiation announced July 28, 2020.
$3.5 billion